Literature DB >> 3986800

Reversal of resistance to rhodamine 123 in adriamycin-resistant Friend leukemia cells.

T J Lampidis, J N Munck, A Krishan, H Tapiero.   

Abstract

Pleiotropic resistance to rhodamine 123 (Rho-123) in Adriamycin (ADM)-resistant Friend leukemia cells was circumvented by cotreatment with 10 microM verapamil. Increased cytotoxicity corresponded to higher intracellular Rho-123 levels. The verapamil-induced increase of drug accumulation in resistant cells is accounted for at least in part by the blockage or slowing of Rho-123 efflux from these cells. In contrast, accumulation and consequent cytotoxicity of Rho-123 in sensitive cells are not increased by verapamil. Similar results were obtained when ADM was used in this cell system. These results suggest that the efflux system for Rho-123 and ADM in sensitive cells is either reduced or absent. Although Rho-123 accumulates specifically in mitochondria and ADM mainly in the nucleus, the loss of these two different classes of compounds from resistant cells appears to occur via a similar or common mechanism. The similarities in drug transport between Rho-123 and ADM may have important implications when applied to an in vivo environment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Enhancement of the cytogenetic efficacy of the antitumor agent bleomycin by the calcium and calmodulin antagonist fendiline.

Authors:  W Scheid; H Traut
Journal:  Experientia       Date:  1988-03-15

2.  Membrane transport changes in an adriamycin-resistant murine leukemia cell line and in its sensitive parental cell line.

Authors:  R Bose; H Y Lam
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Transfer of chloramphenicol-resistant mitochondrial DNA into the chimeric mouse.

Authors:  S E Levy; K G Waymire; Y L Kim; G R MacGregor; D C Wallace
Journal:  Transgenic Res       Date:  1999-04       Impact factor: 2.788

4.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Reversal of multidrug resistance by novel cyclosporin A analogues and the cyclopeptolide SDZ 214-103 biosynthesized in vitro.

Authors:  K Schwabe; G Steinheider; A Lawen; R Traber; A Hildebrandt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability.

Authors:  J M Zijlmans; J W Visser; K Kleiverda; P M Kluin; R Willemze; W E Fibbe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

7.  Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.

Authors:  Augusto Pessina; Arianna Bonomi; Valentina Coccè; Gloria Invernici; Stefania Navone; Loredana Cavicchini; Francesca Sisto; Maura Ferrari; Lucia Viganò; Alberta Locatelli; Emilio Ciusani; Graziella Cappelletti; Daniele Cartelli; Caruso Arnaldo; Eugenio Parati; Giovanni Marfia; Roberto Pallini; Maria Laura Falchetti; Giulio Alessandri
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

8.  Enhancing anti-tumor efficacy of Doxorubicin by non-covalent conjugation to gold nanoparticles - in vitro studies on feline fibrosarcoma cell lines.

Authors:  Michał Wójcik; Wiktor Lewandowski; Magdalena Król; Karol Pawłowski; Józef Mieczkowski; Roman Lechowski; Katarzyna Zabielska
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

Review 9.  Mitochondrial Potassium Channels as Druggable Targets.

Authors:  Antoni Wrzosek; Bartłomiej Augustynek; Monika Żochowska; Adam Szewczyk
Journal:  Biomolecules       Date:  2020-08-18

10.  Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.

Authors:  N Feller; C M Kuiper; J Lankelma; J K Ruhdal; R J Scheper; H M Pinedo; H J Broxterman
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.